Abstract
Migraine is one of the most common neurological disorders that affects young people, causing a considerable degree of disability in the active population, with an enormous consequent socio-economic impact. Despite intensive research, the pathomechanism of migraine is not completely understood and its fully effective therapy remains to be achieved. A number of experimental studies have implicated the importance of magnesium ion in the pathophysiology of this condition. Magnesium has been also administered for both prophylactic and acute therapy in migraine, but the question of its efficacy has not been studied adequately. The data available suggest that magnesium has a potential role in the prophylaxis, but the results in acute therapy are far less convincing. With a good side effect profile, magnesium is a relatively safe drug with a possible beneficial effect in the prophylaxis of migraine headache, and it may have its niche in the treatment of migraine patients. However, the current medical evidence that has accumulated and the fact that there are far more effective treatment possibilities clearly indicate that this drug is definitely not to be used by every migraineur.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersson KE, Vinge E (1990) Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 39:355–373
Banai S, Tzivoni D (1993) Drug therapy for torsade de pointes. J Cardiovasc Electrophysiol 4:206–210
Barbiroli B, Montagna P, Cortelli P, Martinelli P, Sacquegna T, Zaniol P, Lugaresi E (1990) Complicated migraine studied by phosphorus magnetic resonance spectroscopy. Cephalalgia 10:263–272
Barbiroli B, Montagna P, Cortelli P, Funicello R, Iotti S, Monari L, Pierangeli G, Zaniol P, Lugaresi E (1992) Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 42:1209–1214
Bigal ME, Bordini CA, Tepper SJ, Speciali JG (2002) Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia 22:345–353
Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8:136–142
Burstein R, Yamamura H, Malick A, Strassman AM (1998) Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 79:964–982
Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH (2000) An association between migraine and cutaneous allodynia. Ann Neurol 47:614–624
Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C (2005) A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia 25:199–204
Ciarkowski SL, Stalburg CM (2010) Medication safety in obstetrics and gynecology. Clin Obstet Gynecol 53:482–499
Corbo J, Esses D, Bijur PE, Iannaccone R, Gallagher EJ (2001) Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med 38:621–627
Demirkaya S, Vural O, Dora B, Topcuoglu MA (2001) Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache 41:171–177
Diener HC (1997) Positron emission tomography studies in headache. Headache 37:622–625
Ebel H, Gunther T (1980) Magnesium metabolism: a review. J Clin Chem Clin Biochem 18:257–270
Elin RJ (1994) Magnesium: the fifth but forgotten electrolyte. Am J Clin Pathol 102:616–622
Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS (2009) EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol 16:968–981
Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G (1991) Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 31:298–301
Gallai V, Sarchielli P, Morucci P, Abbritti G (1993) Red blood cell magnesium levels in migraine patients. Cephalalgia 13:81–94
Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23:193–196
Grubbs RD, Maguire ME (1987) Magnesium as a regulatory cation: criteria and evaluation. Magnesium 6:113–127
Guerrera MP, Volpe SL, Mao JJ (2009) Therapeutic uses of magnesium. Am Fam Physician 80:157–162
Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, Berbano E, O’Malley PG (2010) Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ 341:c5222
Koseoglu E, Talaslioglu A, Gonul AS, Kula M (2008) The effects of magnesium prophylaxis in migraine without aura. Magnes Res 21:101–108
Lance JW, Lambert GA, Goadsby PJ, Duckworth JW (1983) Brainstem influences on the cephalic circulation: experimental data from cat and monkey of relevance to the mechanism of migraine. Headache 23:258–265
Lauritzen M (1994) Pathophysiology of the migraine aura. The spreading depression theory. Brain 117:199–210
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41:646–657
Maizels M, Blumenfeld A, Burchette R (2004) A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 44:885–890
Mathew PJ, Muthurajan N, Wig J (2010) Progressive muscle weakness with respiratory insufficiency in a young patient with tetanus during magnesium sulfate infusion. Acta Anaesthesiol Taiwan 48:152–154
Mauskop A, Altura BT, Cracco RQ, Altura BM (1993) Deficiency in serum ionized magnesium but not total magnesium in patients with migraines. Possible role of ICa2+/IMg2+ ratio. Headache 33:135–138
Mayer ML, Westbrook GL, Guthrie PB (1984) Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature 309:261–263
Moskowitz MA, Nozaki K, Kraig RP (1993) Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 13:1167–1177
Onalan O, Crystal E, Daoulah A, Lau C, Crystal A, Lashevsky I (2007) Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation. Am J Cardiol 99:1726–1732
Peikert A, Wilimzig C, Kohne-Volland R (1996) Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 16:257–263
Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, Taneri Z, Soyka D, Gobel H, Fischer M (1996) Magnesium in the prophylaxis of migraine—a double-blind placebo-controlled study. Cephalalgia 16:436–440
Ramadan NM, Halvorson H, Vande-Linde A, Levine SR, Helpern JA, Welch KM (1989) Low brain magnesium in migraine. Headache 29:416–419
Rothrock JF (1997) Clinical studies of valproate for migraine prophylaxis. Cephalalgia 17:81–83
Rude RK, Shils ME (2006) Magnesium. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ (eds) Modern Nutrition in Health and Disease, 10th edn. Lippincott Williams & Wilkins, Baltimore, pp 223–248
Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J (2005) Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64:713–715
Schoenen J, Jacquy J, Lenaerts M (1998) Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50:466–470
Smeets MC, Vernooy CB, Souverijn JH, Ferrari MD (1994) Intracellular and plasma magnesium in familial hemiplegic migraine and migraine with and without aura. Cephalalgia 14:29–32
Strassman AM, Raymond SA, Burstein R (1996) Sensitization of meningeal sensory neurons and the origin of headaches. Nature 384:560–564
Taubert K (1994) Magnesium in migraine. Results of a multicenter pilot study. Fortschr Med 112:328–330
Trauninger A, Pfund Z, Koszegi T, Czopf J (2002) Oral magnesium load test in patients with migraine. Headache 42:114–119
Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ (2003) Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 43:601–610
Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC (1995) Brain stem activation in spontaneous human migraine attacks. Nat Med 1:658–660
Welch KM, Levine SR, D’Andrea G, Schultz LR, Helpern JA (1989) Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 39:538–541
Welch KM, Nagesh V, Aurora SK, Gelman N (2001) Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 41:629–637
Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997) Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia 17:518–524
Witlin AG, Sibai BM (1998) Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet Gynecol 92:883–889
Young WB, Siow HC, Silberstein SD (2004) Anticonvulsants in migraine. Curr Pain Headache Rep 8:244–250
Acknowledgments
This work was supported by TÁMOP-4.2.1/B-09/1/KONV-2010-0005—Creating the Center of Excellence at the University of Szeged and ETT 026-04, OTKA K75628 grants. Thanks are due to David Durham for the linguistic corrections.